Refractory Migraine
Refractory migraine refers to migraine that fails to respond adequately to multiple standard preventive and acute treatments. There is no universally accepted definition, but the AHS/EHF propose criteria requiring failure of at least 3 preventive classes and 3 acute medication classes. These patients represent 3-5% of the migraine population and require systematic evaluation, multi-modal therapy, and often combination treatments. Before labeling migraine as refractory, it is essential to address modifiable factors including medication overuse, comorbid conditions, and treatment adequacy.
Bottom Line
- Definition: Failure of ≥3 preventive medication classes at adequate dose/duration AND inadequate response to ≥3 acute treatments (including triptans)
- Before calling it refractory: Rule out medication overuse headache, confirm diagnosis, address comorbidities (anxiety, depression, sleep disorders), and ensure prior treatments were given adequate trials
- Combination therapy: The cornerstone of refractory management — combining treatments from different mechanism classes (e.g., Botox + CGRP mAb + nerve blocks)
- CGRP mAbs after Botox failure: 30-40% of Botox non-responders respond to CGRP mAbs (different mechanism)
- Procedural options: Serial nerve blocks, trigger point injections, IV infusion protocols, and neuromodulation devices
- Multidisciplinary approach: Behavioral therapy, physical therapy, and biofeedback should always be part of the plan
Defining Refractory Migraine
| Criterion | Requirement |
|---|---|
| Diagnosis | ICHD-3 migraine (episodic or chronic) |
| Preventive failures | Failure of ≥3 classes at adequate dose for ≥8 weeks each: • Beta-blocker (propranolol ≥120 mg or equivalent) • Antiepileptic (topiramate ≥100 mg or valproate ≥500 mg) • TCA or SNRI (amitriptyline ≥50 mg or venlafaxine ≥150 mg) • OnabotulinumtoxinA (≥2 cycles of 155 U) • CGRP mAb (≥3 months) |
| Acute treatment failures | Inadequate response to ≥3 acute medications including: • At least 2 triptans (different routes) • NSAID or combination analgesic • Gepant or ditan |
| Modifiable factors addressed | Medication overuse eliminated, comorbidities treated, lifestyle modifications implemented |
Systematic Evaluation
Before Labeling Migraine as Refractory
- Confirm the diagnosis: Review ICHD-3 criteria. Consider secondary headache mimics (especially in progressive or atypical presentations). CSF pressure disorders, cervicogenic headache, and occipital neuralgia may masquerade as refractory migraine.
- Medication overuse: Present in up to 50% of patients referred for refractory migraine. Must be addressed first — no preventive works optimally in the setting of MOH.
- Adequate trials? Many “failures” were at subtherapeutic doses or inadequate duration. Topiramate at 25 mg for 3 weeks is not a fair trial. Review each prior treatment systematically.
- Comorbidities: Depression, anxiety, PTSD, insomnia, and sleep apnea all worsen migraine and must be treated concurrently. Untreated comorbidities are the most common reason for apparent treatment resistance.
- Expectations: Patients may expect complete headache elimination. A realistic goal is ≥50% reduction in headache days and improved function — not necessarily headache freedom.
Combination Preventive Therapy
The key principle in refractory migraine is combining treatments from different mechanistic classes for additive or synergistic benefit.
| Combination | Evidence | Rationale |
|---|---|---|
| OnabotulinumtoxinA + CGRP mAb | Growing real-world evidence. Blumenfeld (2021): erenumab add-on reduced migraine days by 4.4 additional days. Ailani (2022): 54% of Botox partial responders achieved ≥50% response after adding fremanezumab. | Complementary mechanisms: Botox blocks CGRP release; mAbs block CGRP in extracellular space |
| CGRP mAb + oral preventive | Permitted in pivotal trials. No pharmacokinetic interactions. Subgroup analyses show additive benefit. | mAb targets CGRP pathway; oral agent targets different pathway (beta-blocker, TCA, antiepileptic) |
| Botox + oral preventive | Common practice. No interaction data concerns. | Different targets; oral agents fill gaps between Botox cycles |
| Triple therapy (Botox + CGRP mAb + oral) | Case series only. Used in tertiary headache centers. | Maximum mechanism coverage for most refractory patients |
| Any preventive + nerve blocks | Widely used as adjunct. GON blocks every 2-4 weeks. | Addresses peripheral trigeminal sensitization; immediate relief while preventives take effect |
| Any preventive + neuromodulation | Device therapy (Cefaly, sTMS, Nerivio) can be added to any regimen without interaction. | Non-pharmacologic layer with no drug interactions |
Switching Within CGRP Class
- Failure of one CGRP mAb does not predict failure of others. Antibody targets differ: erenumab targets the CGRP receptor; galcanezumab, fremanezumab, and eptinezumab target the CGRP ligand.
- Switch evidence: 30-40% of patients who fail one CGRP mAb respond to a different one (retrospective series)
- mAb to gepant: Patients failing CGRP mAbs may respond to oral gepants (different pharmacology — small molecule competitive antagonist vs large molecule binding)
- Eptinezumab (IV): Consider for patients failing SC mAbs. 100% bioavailability with IV dosing; quarterly infusion.
Procedural Interventions
| Procedure | Frequency | Role in Refractory Migraine |
|---|---|---|
| GON block (+ LON, supraorbital) | Every 2-4 weeks | Bridge therapy; ongoing adjunct. Can use combined block (GON + frontal nerves bilaterally) for broader coverage. |
| SPG block (intranasal) | Twice weekly for 6 weeks (Cady protocol), then as needed | Targets parasympathetic pathway; may reduce attack frequency in chronic migraine |
| Trigger point injections | Every 4-6 weeks | Addresses pericranial muscle tenderness and peripheral sensitization. Trapezius, temporalis, SCM. |
| IV infusion protocol | As needed for prolonged attacks | Magnesium 2g + ketorolac 30mg + metoclopramide 10mg + dexamethasone 8mg +/- valproate 500-1000mg IV. Series of 3-5 infusions over 5-10 days for intractable migraine. |
| Ketamine infusion | Specialized centers only | Sub-anesthetic IV ketamine (0.1-0.5 mg/kg/hour) over 3-7 days. NMDA antagonism may reset central sensitization. Limited evidence; used in tertiary centers for most refractory cases. |
Multidisciplinary Management
The Complete Refractory Migraine Program
- Behavioral therapy (CBT): Level A evidence. Addresses pain catastrophizing, avoidance behavior, and maladaptive coping. Essential, not optional, in refractory patients.
- Biofeedback: Thermal or EMG biofeedback. Level A evidence. Particularly useful for patients who want active participation in their treatment.
- Physical therapy: Targets cervicogenic contributions, postural dysfunction, and pericranial myofascial pain. Cervical spine manual therapy reduces headache frequency in patients with neck involvement.
- Psychology/psychiatry: Treat comorbid depression, anxiety, and PTSD. Address sleep disorders (CBT-I for insomnia). Consider that untreated psychiatric comorbidity is the number one barrier to migraine treatment success.
- Lifestyle optimization: Consistent sleep-wake schedule, regular exercise (150 min/week), hydration, stress management, and trigger avoidance. These fundamentals must be reinforced even in highly treated patients.
- Pain rehabilitation programs: Intensive outpatient or inpatient multidisciplinary headache programs (e.g., MIDAS, Mayo, Jefferson, Diamond) for the most refractory patients. Combine medication optimization, medication withdrawal, behavioral therapy, physical therapy, and infusion therapy over 2-3 weeks.
Investigational and Emerging Approaches
- Psilocybin: Phase 2 trials ongoing for migraine prevention. Preliminary data suggest a single dose may reduce migraine frequency for weeks. Mechanism likely involves 5-HT2A-mediated neuroplasticity.
- Invasive neuromodulation: Occipital nerve stimulation (ONS) has mixed RCT data; reserved for most refractory cases. SPG stimulation via implanted device (Pulsante) showed efficacy in cluster headache; migraine data pending.
- Monoclonal antibodies targeting PACAP: PACAP (pituitary adenylate cyclase-activating polypeptide) is a second neuropeptide pathway implicated in migraine. Anti-PACAP antibodies are in early clinical development.
- Novel oral targets: Orexin receptor antagonists, glutamate modulators, and neurosteroids are in preclinical or early clinical development for migraine.
Management Algorithm
Stepwise Approach to Refractory Migraine
- Re-evaluate: Confirm diagnosis, eliminate MOH, treat comorbidities, verify adequate prior treatment trials
- Optimize current regimen: Maximize dose of current preventive, add behavioral therapy and lifestyle interventions
- Combine mechanisms: Add a treatment from a different class (e.g., if on Botox, add CGRP mAb; if on oral preventive, add nerve blocks)
- Switch within CGRP class: Try a different mAb or switch mAb → gepant
- Procedural layer: Add serial nerve blocks, SPG blocks, or neuromodulation devices
- Infusion therapy: Outpatient IV infusion series for acute exacerbations or prolonged attacks
- Intensive rehabilitation: Refer to multidisciplinary headache center for comprehensive inpatient/outpatient program
- Investigational: Clinical trial enrollment for novel targets (PACAP, psilocybin, neuromodulation)
References
- Schulman EA, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008;48(6):778-782.
- Blumenfeld AM, et al. Real-world evidence for the addition of CGRP monoclonal antibodies to onabotulinumtoxinA treatment for migraine. Headache. 2021;61(8):1246-1256.
- Ailani J, et al. Fremanezumab in patients with chronic migraine and comorbid depression or anxiety: post hoc analysis of a randomized trial. Headache. 2022;62(1):34-46.
- Sacco S, et al. European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6.
- Schwedt TJ, et al. Comprehensive systematic review and evidence-based guidelines for the management of refractory migraine. Headache. 2022;62(9):1169-1186.